Literature DB >> 28941830

Experimental and computational study of the effect of breath-actuated mechanism built in the NEXThaler® dry powder inhaler.

Árpád Farkas1, David Lewis2, Tanya Church2, Alan Tweedie2, Francesca Mason2, Allen E Haddrell3, Jonathan P Reid3, Alpár Horváth4, Imre Balásházy5.   

Abstract

The breath-actuated mechanism (BAM) is a mechanical unit included in NEXThaler® with the role of delaying the emission of the drug until the inhalation flow rate of the patient is sufficiently high to detach the drug particles from their carriers. The main objective of this work was to analyse the effect of the presence of BAM on the size distribution of the emitted drug and its airway deposition efficiency and distribution. Study of the hygroscopic growth of the emitted drug particles and its effect on the deposition was another goal of this study. Size distributions of Foster® NEXThaler® drug particles emitted by dry powder inhalers with and without BAM have been measured by a Next Generation Impactor. Three characteristic inhalation profiles of asthmatic patients (low, moderate and high flow rates) were used for both experimental and modelling purposes. Particle hygroscopic growth was determined by a new method, where experimental measurements are combined with simulations. Upper airway and lung deposition fractions were computed assuming 5s and 10s breath-hold times. By the inclusion of BAM the fine particle fraction of the steroid component increased from 24 to 30% to 47-51%, while that of bronchodilator from 25-34% to 52-55%. The predicted upper airway steroid and bronchodilator doses decreased from about 60% to 35-40% due to BAM. At the same time, predicted lung doses increased from about 20%-35% (steroid) and from 22% to 38% (bronchodilator) for the moderate flow profile and from about 25% to 40% (steroid) and from 29% to 47% (bronchodilator) for the high inhalation flow profile. Although BDP and FF upper airway doses decreased by a factor of about two when BAM was present, lung doses of both components were about the same in the BAM and no-BAM configurations at the weakest flow profile. However, lung dose increased by 2-3% even for this profile when hygroscopic growth was taken into account. In conclusion, the NEXThaler® BAM mechanism is a unique feature enabling high emitted fine particle fraction and enhanced drug delivery to the lungs.
Copyright © 2017 The Authors. Published by Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Aerosol drug targeting; Airway deposition modelling; Beclomethasone dipropionate; Breath-actuated mechanism; Formoterol fumarate; Hygroscopic growth; Particle size distribution

Mesh:

Substances:

Year:  2017        PMID: 28941830     DOI: 10.1016/j.ijpharm.2017.09.057

Source DB:  PubMed          Journal:  Int J Pharm        ISSN: 0378-5173            Impact factor:   5.875


  2 in total

1.  Dose-response of an extrafine dry powder inhaler formulation of glycopyrronium bromide: randomized, double-blind, placebo-controlled, dose-ranging study (GlycoNEXT).

Authors:  Kai M Beeh; Aida Emirova; Hélène Prunier; Debora Santoro; Marie Anna Nandeuil
Journal:  Int J Chron Obstruct Pulmon Dis       Date:  2018-05-25

2.  Inspiratory flow profile and usability of the NEXThaler, a multidose dry powder inhaler, in asthma and COPD.

Authors:  Alfredo Chetta; Arzu Yorgancioglu; Mario Scuri; Sara Barile; Daniele Guastalla; P N Richard Dekhuijzen
Journal:  BMC Pulm Med       Date:  2021-02-25       Impact factor: 3.317

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.